Home › Research › Biomarkers
Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts
Rebecca A. Deek, Wasiu G. Balogun, Xuemei Zeng, Gallen Triana-Baltzer, Tharick A. Pascoal, Hartmuth C. Kolb, Beth Snitz, Ann D. Cohen, Thomas K. Karikari. Alzheimer's Research & Therapy, 2026-02-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This study directly compared four different commercial/lab p-tau217 blood tests (Lumipulse, ALZpath, Johnson & Johnson, and NULISA) in 344 people from two community cohorts, most of whom were cognitively normal or had only mild changes. All four tests were reasonably consistent with each other and similarly good at detecting amyloid buildup, but none of them were very good at detecting tau tangle spread, suggesting these blood tests are better suited to flagging amyloid than tau pathology at this early stage.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 344 participants. Four different p-tau217 blood tests were similarly good at detecting amyloid buildup (AUC 0.84-0.90) but all performed poorly at detecting tau tangles (AUC 0.52-0.61) in mostly cognitively normal people. Reported effect size: Cross-platform correlations 0.40-0.86; AUC 0.84-0.90 for amyloid-PET positivity; AUC 0.52-0.61 for tau pathology.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Deek, R. A., Balogun, W. G., Zeng, X., Triana-Baltzer, G., Pascoal, T. A., Kolb, H. C., et al. (2026). Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts. Alzheimer's Research & Therapy.
Vancouver
Deek RA, Balogun WG, Zeng X, Triana-Baltzer G, Pascoal TA, Kolb HC, et al. Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts. Alzheimer's Research & Therapy. 2026.
BibTeX
@article{deek2026-c113f7bd,
author = {Deek, Rebecca A. and Balogun, Wasiu G. and Zeng, Xuemei and Triana-Baltzer, Gallen and Pascoal, Tharick A. and Kolb, Hartmuth C. and Snitz, Beth and Cohen, Ann D. and Karikari, Thomas K.},
title = {{Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts}},
journal = {Alzheimer's Research \& Therapy},
year = {2026}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- 344 participants across two community cohorts (median ages 62 and 76)
- Cross-platform correlations of 0.40-0.86 between the four assays
- All four assays: AUC 0.84-0.90 for amyloid-PET positivity
- All four assays performed substantially worse for tau pathology detection (AUC 0.52-0.61)
Why it matters
Four different p-tau217 blood tests were similarly good at detecting amyloid buildup (AUC 0.84-0.90) but all performed poorly at detecting tau tangles (AUC 0.52-0.61) in mostly cognitively normal people. This suggests these blood tests are better suited to flagging amyloid than tau pathology at this early stage, and it is a diagnostic comparison, not a treatment finding.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants344
- Effect sizeCross-platform correlations 0.40-0.86; AUC 0.84-0.90 for amyloid-PET positivity; AUC 0.52-0.61 for tau pathology
- Evidence strengthModerate
Limitations
Community cohorts skew toward early/preclinical disease stages, limiting generalizability to more advanced dementia populations.
How this study scored 60/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 37 of the 62 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's Research & Therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 344 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 37 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 37 of the 62 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.